Andrew D. Hershey, MD, PhD Headache Center, Division of Neurology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Curr Treat Options Neurol. 2007 Jan;9(1):14-22. doi: 10.1007/s11940-007-0026-1.
Very limited long-term follow-up data exist for the population of children and adolescents with chronic daily headache (CDH). One abstracted report discusses short-term follow-up on 24 adolescents (peak age 13 years) with CDH; in a 6-month follow-up, more than 50% experienced a reduction of 75% or more in headache frequency, and one third showed an improvement of greater than 90% in headache frequency. A wide variety of preventive agents were used, but amitriptyline and topiramate provided the largest percentage of successful outcomes. With an improving classification scheme, we have the possibility of using multicenter studies to elucidate whether the clinical patterns seen by experienced observers translate into rational differentiation of treatment approaches. If the entities of CDH are, indeed, different, then therapeutic, prophylactic, and behavioral trials could guide us in offering a more evidence-based approach to the treatment of this fascinating, yet sometimes debilitating condition.
针对患有慢性每日头痛(CDH)的儿童和青少年人群,目前仅有非常有限的长期随访数据。有一份摘要报告讨论了对 24 名 CDH 青少年(发病高峰年龄为 13 岁)的短期随访情况;在 6 个月的随访中,超过 50%的患者头痛频率降低了 75%或更多,三分之一的患者头痛频率改善了 90%以上。使用了各种各样的预防药物,但阿米替林和托吡酯提供了最大比例的成功结果。随着分类方案的不断完善,我们有可能利用多中心研究来阐明经验丰富的观察者所看到的临床模式是否转化为合理的治疗方法区分。如果 CDH 的实体确实不同,那么治疗、预防和行为试验可以指导我们采用更基于证据的方法来治疗这种引人入胜但有时使人衰弱的疾病。